Structured Review

Charles River Laboratories osmotic minipumps
Osmotic Minipumps, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/osmotic minipumps/product/Charles River Laboratories
Average 92 stars, based on 1 article reviews
Price from $9.99 to $1999.99
osmotic minipumps - by Bioz Stars, 2020-07
92/100 stars

Images

Related Articles

Flow Cytometry:

Article Title: Novel Control by the CA3 Region of the Hippocampus on Neurogenesis in the Dentate Gyrus of the Adult Rat
Article Snippet: .. Rats (n = 5 per group) received CA3 lesions on day1, and were also implanted with subcutaneous osmotic minipumps in the posterior upper thorax (model 2ML2 the rate of flow is 5 µl/hr for 14 days) (Charles River, Margate, UK, catalogue number 2ML2) filled either with fluoxetine (releasing 10 mg/kg/day dissolved directly in saline under running hot tap water or saline, therefore for animals weighing 250 gm they would receive 46.6 mg of fluoxetine in one osmotic minipump,. ..

other:

Article Title: Phospholipid membranes drive abdominal aortic aneurysm development through stimulating coagulation factor activity
Article Snippet: Osmotic minipumps (model 1002; Charles River) delivering saline or Ang II (1 mg⋅kg−1 per day; Sigma-Aldrich) for 14 d were implanted s.c. in the midscapular region under aseptic conditions.

Article Title: A Pharmacologically Active Monoclonal Antibody against the Human Melanocortin-4 Receptor: Effectiveness After Peripheral and Central Administration
Article Snippet: Osmotic minipumps (model 2002) (Charles River Laboratories, Les Oncins, France) were filled with mAbs 1E8a or 2G2 calculated to deliver 1 μg/day for 7 days.

Article Title: Rescue of arterial function by angiotensin-(1-7): towards improvement of endothelial function by drug-eluting stents
Article Snippet: To test the effect of Ang-(1-7) infusion, bare metal stents (2.5 x 9 mm Medtronic Be-Stent coronary stents) were placed in abdominal aorta, and osmotic minipumps (Model 2004, Alzet, Charles River, Maastricht, the Netherlands) were implanted, as previously described.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Charles River Laboratories alzet osmotic minipumps
    Uncl-Sema3E inhibits angiogenesis and tumour growth in the RIP-Tag2 model <t>Alzet</t> <t>minipumps</t> were implanted in 12-week-old RT2 mice to release locally in the pancreas Uncl-Sema3E ( n = 14) or mock saline ( n = 12) over a period of 2 weeks; other mice were treated orally with sunitinib ( n = 8) for the same period (see Materials and Methods Section for details); two independent experiments were performed, yielding consistent results. Average global tumour burden per mice in different experimental conditions. Vessel area in treated tumours was estimated based on CD31 staining ( n = 6, per each experimental group). Vessel coverage with mural cells was assessed by double staining for NG2 and CD31 ( n = 6). Hypoxic areas in islet tumours were revealed by staining with pimonidazol (PIMO, see Materials and Methods Section; n = 6); the same sections were costained with the endothelial cell marker Endoglin-CD105, and with DAPI. Primary RT2 tumour invasiveness was assessed by morphometric analysis of H E stained sections, as previously reported (Pàez-Ribes et al, 2009 ). Representative images of the different groups are shown on the right. Uncl-Sema3E treated tumours often displayed a non-invasive phenotype: i.e. the tumour was ‘encapsulated’ and well separated from the surrounding exocrine tissue (delimited by a dotted line). In contrast, in sunitinib-treated mice the tumour invasive front was often extensively intercalated with the surrounding normal exocrine tissue. The graph on the left indicates the average fraction of encapsulated (IT), microinvasive (IC1) and highly invasive (IC2) carcinomas per mice in each experimental condition ( n = 8). We assessed the statistical significance of the different relative representation of each tumour histotype in drug-treated versus mock control mice; * p = 0.003; ** p = 0.007; § p = 6.1E−05; §§ p = 1.7E−06. Scale bars, throughout the entire figure: 100 µm (20 µm in magnified insets in panel C ).
    Alzet Osmotic Minipumps, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 92/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/alzet osmotic minipumps/product/Charles River Laboratories
    Average 92 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    alzet osmotic minipumps - by Bioz Stars, 2020-07
    92/100 stars
      Buy from Supplier

    Image Search Results


    Uncl-Sema3E inhibits angiogenesis and tumour growth in the RIP-Tag2 model Alzet minipumps were implanted in 12-week-old RT2 mice to release locally in the pancreas Uncl-Sema3E ( n = 14) or mock saline ( n = 12) over a period of 2 weeks; other mice were treated orally with sunitinib ( n = 8) for the same period (see Materials and Methods Section for details); two independent experiments were performed, yielding consistent results. Average global tumour burden per mice in different experimental conditions. Vessel area in treated tumours was estimated based on CD31 staining ( n = 6, per each experimental group). Vessel coverage with mural cells was assessed by double staining for NG2 and CD31 ( n = 6). Hypoxic areas in islet tumours were revealed by staining with pimonidazol (PIMO, see Materials and Methods Section; n = 6); the same sections were costained with the endothelial cell marker Endoglin-CD105, and with DAPI. Primary RT2 tumour invasiveness was assessed by morphometric analysis of H E stained sections, as previously reported (Pàez-Ribes et al, 2009 ). Representative images of the different groups are shown on the right. Uncl-Sema3E treated tumours often displayed a non-invasive phenotype: i.e. the tumour was ‘encapsulated’ and well separated from the surrounding exocrine tissue (delimited by a dotted line). In contrast, in sunitinib-treated mice the tumour invasive front was often extensively intercalated with the surrounding normal exocrine tissue. The graph on the left indicates the average fraction of encapsulated (IT), microinvasive (IC1) and highly invasive (IC2) carcinomas per mice in each experimental condition ( n = 8). We assessed the statistical significance of the different relative representation of each tumour histotype in drug-treated versus mock control mice; * p = 0.003; ** p = 0.007; § p = 6.1E−05; §§ p = 1.7E−06. Scale bars, throughout the entire figure: 100 µm (20 µm in magnified insets in panel C ).

    Journal: EMBO Molecular Medicine

    Article Title: Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform

    doi: 10.1002/emmm.201100205

    Figure Lengend Snippet: Uncl-Sema3E inhibits angiogenesis and tumour growth in the RIP-Tag2 model Alzet minipumps were implanted in 12-week-old RT2 mice to release locally in the pancreas Uncl-Sema3E ( n = 14) or mock saline ( n = 12) over a period of 2 weeks; other mice were treated orally with sunitinib ( n = 8) for the same period (see Materials and Methods Section for details); two independent experiments were performed, yielding consistent results. Average global tumour burden per mice in different experimental conditions. Vessel area in treated tumours was estimated based on CD31 staining ( n = 6, per each experimental group). Vessel coverage with mural cells was assessed by double staining for NG2 and CD31 ( n = 6). Hypoxic areas in islet tumours were revealed by staining with pimonidazol (PIMO, see Materials and Methods Section; n = 6); the same sections were costained with the endothelial cell marker Endoglin-CD105, and with DAPI. Primary RT2 tumour invasiveness was assessed by morphometric analysis of H E stained sections, as previously reported (Pàez-Ribes et al, 2009 ). Representative images of the different groups are shown on the right. Uncl-Sema3E treated tumours often displayed a non-invasive phenotype: i.e. the tumour was ‘encapsulated’ and well separated from the surrounding exocrine tissue (delimited by a dotted line). In contrast, in sunitinib-treated mice the tumour invasive front was often extensively intercalated with the surrounding normal exocrine tissue. The graph on the left indicates the average fraction of encapsulated (IT), microinvasive (IC1) and highly invasive (IC2) carcinomas per mice in each experimental condition ( n = 8). We assessed the statistical significance of the different relative representation of each tumour histotype in drug-treated versus mock control mice; * p = 0.003; ** p = 0.007; § p = 6.1E−05; §§ p = 1.7E−06. Scale bars, throughout the entire figure: 100 µm (20 µm in magnified insets in panel C ).

    Article Snippet: Alzet osmotic minipumps (2002 model, Charles River Laboratories) were used to accomplish local delivery of Uncl-Sema3E in the pancreas of experimental mice between 12 and 14 weeks of age (see Supporting Information Methods for details).

    Techniques: Mouse Assay, Staining, Double Staining, Marker